When AI is grounded in rigorous, peer-reviewed science, discovery improves outcomes

In early drug discovery, the limiting factor is often not expertise. It is access to evidence at scale.

Data is spread across journals and patents. Patents are dense, inconsistently indexed, and often untranslated, so assembling what matters can take weeks.

By embedding Reaxys, Elsevier’s chemistry intelligence platform, into AI supported workflows, teams can bring chemical, bioactivity, and patent evidence together, with every insight traceable back to the source. Built in translation and indexing helps reduce the risk of missing something important.

The difference is practical. Days instead of weeks. Decisions made with context, not guesswork.

Read more: http://spkl.io/6044AAjGO